(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 October 2012 (26.10.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/145673 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/US2012/034519

(22) International Filing Date:
20 April 2012 (20.04.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/477,904 21 April 2011 (21.04.2011) US

(71) Applicants *(for all designated States except US)*: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **DOMANTIS LIMITED** [GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SURI, Anish** [US/US]; Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **SHERIFF, Steven** [US/US]; Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **SUCHARD, Suzanne** [US/US]; Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **YAMNIUK, Aaron** [CA/US]; Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **KRYSTEK, Stanley** [US/US]; Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **TAMURA, James** [US/US]; Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **BRYSON, James** [US/US]; Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **GRANT, Steven** [GB/GB]; Domantis Limited, 315 Cambridge Science Park, Cambridge Cambridgeshire CB4 0WG (GB). **DREW, Philip** [GB/GB]; 315 Cambridge Science Park, Cambridge Cambridgeshire CB4 0WG (GB).


(74) Agents: **MEYER, Mercedes K.** et al.; Drinker Biddle & Reath LLP, 1500 K Street, N.W., Suite 1100, Washington, District of Columbia 20005-1209 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,

[Continued on next page]

(54) Title: ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40

FIG. 1



(57) Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V_L or V_H domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).

WO 2012/145673 A1

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*